Galera Therapeutics Stock Price To Earnings To Growth
Galera Therapeutics fundamentals help investors to digest information that contributes to Galera Therapeutics' financial success or failures. It also enables traders to predict the movement of Galera Pink Sheet. The fundamental analysis module provides a way to measure Galera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galera Therapeutics pink sheet.
Galera |
Galera Therapeutics Company Price To Earnings To Growth Analysis
Galera Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Galera Therapeutics Price To Earnings To Growth | (0.02) X |
Most of Galera Therapeutics' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Galera Therapeutics has a Price To Earnings To Growth of -0.02 times. This is 102.82% lower than that of the Biotechnology sector and 100.64% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.41% higher than that of the company.
Galera Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galera Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Galera Therapeutics could also be used in its relative valuation, which is a method of valuing Galera Therapeutics by comparing valuation metrics of similar companies.Galera Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
Galera Fundamentals
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 36.15 % | ||||
| Shares Owned By Institutions | 18.95 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) | ||||
| Net Income | (59.08 M) | ||||
| Cash And Equivalents | 52.01 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 152.3 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 5.02 X | ||||
| Book Value Per Share | (2.48) X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Short Ratio | 1.16 X | ||||
| Earnings Per Share | (0.91) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 0.5 | ||||
| Beta | 2.03 | ||||
| Market Capitalization | 7.89 M | ||||
| Total Asset | 26.14 M | ||||
| Retained Earnings | (437.41 M) | ||||
| Working Capital | 16.67 M | ||||
| Current Asset | 36.65 M | ||||
| Current Liabilities | 5.37 M | ||||
| Net Asset | 26.14 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |